J
5.50
-0.18 (-3.17%)
| Previous Close | 5.68 |
| Open | 5.62 |
| Volume | 175,039 |
| Avg. Volume (3M) | 205,771 |
| Market Cap | 82,621,552 |
| Price / Book | 1.82 |
| 52 Weeks Range | |
| Earnings Date | 11 Aug 2025 - 15 Aug 2025 |
| Diluted EPS (TTM) | -5.27 |
| Total Debt/Equity (MRQ) | 6.13% |
| Current Ratio (MRQ) | 4.31 |
| Operating Cash Flow (TTM) | -69.71 M |
| Levered Free Cash Flow (TTM) | -43.72 M |
| Return on Assets (TTM) | -56.50% |
| Return on Equity (TTM) | -101.34% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Jasper Therapeutics, Inc. | Bullish | Bearish |
AIStockmoo Score
0.6
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.63 |
|
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 1.27% |
| % Held by Institutions | 87.97% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Qiming U.S. Ventures Management, Llc | 31 Mar 2025 | 928,964 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 65.00 (Oppenheimer, 1,081.82%) | Buy |
| Median | 49.00 (790.91%) | |
| Low | 33.00 (UBS, 500.00%) | Buy |
| Average | 49.00 (790.91%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 4.85 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Oppenheimer | 15 May 2025 | 65.00 (1,081.82%) | Buy | 4.87 |
| UBS | 13 May 2025 | 33.00 (500.00%) | Buy | 4.82 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 14 Jun 2025 | Announcement | Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria |
| 03 Jun 2025 | Announcement | Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress |
| 14 May 2025 | Announcement | Jasper Therapeutics to Present at Upcoming Investor Conferences |
| 12 May 2025 | Announcement | Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |